Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2019 | Story Rulanzen Martin | Photo Sonia Small (Kaleidoscope Studios)
#UFSRun4MentalHealth
The #UFSRun4MentalHealth is an initiative to create awareness around mental health.

Bringing hope to the millions of South Africans suffering from mental illness, is the message the #UFSRun4MentalHealth team wants to resonate when they take on the 1 075 km distance between Bloemfontein and Stellenbosch.  

On Friday 20 September 2019, three teams of enthusiastic runners from the Faculty of Health Sciences and Organisational Development and Employee Wellness at the University of the Free State (UFS) will embark on the first UFS mental-health awareness run to Stellenbosch. Each runner will complete 9 km each day. “We will be passing on the baton of hope. There is hope, and no one is alone,” says Burneline Kaars, Head of Employee Wellness at the UFS. 

The #UFSRun4MentalHealth run will end on the campus of Stellenbosch University (SU) on 25 September 2019, with the symbolic handover of the baton of hope to a representative of the SU management. 

Team Blue

Team Blue. From the left: Jo-mari Horn, Patrick Kaars, Burneline Kaars, Riaan Bezuidenhout, George Dumisi, and Eugene Petrus.
(absent: Hendrik Blom)

#UFSRun4MentalHealth part of larger project

“This initiative is our effort to mitigate the impact of inactivity experienced by our students and staff on their productivity and mental health. The purpose is to raise awareness and motivate people to get active,” says Burneline. Through this effort, the UFS is demonstrating care for student and staff well-being. 

“Well-being is not only the responsibility of the organisation or university, but the responsibility of all of us,” says Prof Francis Petersen, Rector and Vice-Chancellor. “This initiative also demonstrates care – to look after one another, to take care of one another –from the organisation to our people, but also among ourselves.” 

Prof Petersen points out that the #UFSRun4MentalHealth forms part of a larger UFS project called ‘Project Caring’. He is also hopeful that the team’s effort to change the perception of mental health will encourage discussion and openness in the towns they will visit on their way to Stellenbosch.

Team Red. From the left: Arina Meyer, Nico Piedt, Brenda Coetzee, Justin Coetzee, Elna de Waal, De Wet Dimo, and Tertia de Bruin.

Team Red. From the left: Arina Meyer, Nico Piedt, Brenda Coetzee, Justin Coetzee, Elna de Waal, De Wet Dimo, and Tertia
de Bruin.

Putting care into action

“With this run to Stellenbosch, we are putting care into action,” says Susan van Jaarsveld, Senior Director, Human Resources. 
According to the South African Depression and Anxiety Group, 16% or about 9 million of South Africa’s adult population suffer from a mental disorder. “With this increased awareness, we hope that people will share their mental-health diagnoses and that this campaign will help to reduce the stigma surrounding mental health.”  

The #UFSRun4MentalHealth also links to the mission of the UFS Department of Human Resources to create an environment not only for high performance, but for optimal performance.

The sponsors of this initiative are BestMed, Standard Bank, Shell, Annique Health and Beauty, Xerox, Bidvest Car Rental, Media24, Kloppers, New Balance, Clover, Futurelife, Mylan, Pharma Dynamics, and the SA Society of Psychiatrists

Team White. From the left: Thys Pretorius, Lynette van der Merwe, Leon Engelbrecht, Arina Engelbrecht, Teboho Rampheteng, Belinda Putter, and Lucas Swart.

Team White. From the left: Thys Pretorius, Lynette van der Merwe, Leon Engelbrecht, Arina Engelbrecht, Teboho Rampheteng,
Belinda Putter, and Lucas Swart.

 


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept